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ABSTRACT

A method of sensing glucose in subjects includes the steps of
providing a sensing solution including a plurality of metal
ions, introducing a bodily fluid sample from a subject into the
sensing solution. An optically-based measurable derived
from directing incident light on the solution is generated. The
concentration of glucose in the bodily fluid using the measurable is then determined which permits the blood glucose level
to be derived.
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NONINVASIVE GLUCOSE MONITOR

converted into a glucose concentration. After 72 hours of
measurements, the device is removed and plugged into a
docking station to download its readings.
The docking station can be connected to a computer that
contains dedicated software for use with the system. The
computer will then print out a graph of the three days' blood
glucose readings. The CGMS must be recalibrated with a
fingerstick blood glucose reading at least four times per day.
The GLUCOWATCH G2 Biographer is worn attached to
the wrist, forearm or arm, like a wristwatch. The device
measures blood glucose in real time with new readings displayed every 10 minutes and a trend arrow to indicate whether
the blood glucose level is rising or falling. Both of these
continuous monitors measure the glucose concentration
within interstitial fluid glucose.
The GLUCOWATCH® G2 Biographer contains two electrodes, which pull salt from the skin, the salt carries water, and
the water carries glucose. The glucose solution, which is a
form of diluted interstitial fluid, is collected into a pad called
an Auto sensor. The Auto sensor component of the GLUCOWATCH® G2 Biographer must be replaced after 13 hours of
readings are made. The glucose concentration is determined
by an electrochemical reaction in the Autosensor. A calculation of the blood glucose level is made every ten minutes. A
glucose reading is displayed on the watch face every twenty
minutes.
As described above, both the CGMS and GLUCOWATCH® are invasive. Even a contact lens for monitoring
glucose is somewhat invasive, besides being uncomfortable.
What is needed is a portable, low cost, truly noninvasive
glucose sensor that provides high sensitivity and no discomfort to the patient.

CROSS-REFERENCE TO RELATED
APPLICATIONS
The present application claims priority to U.S. Provisional
Patent Application Ser. No. 60/839,757 filed Aug. 24, 2006,
entitled "NONINVASIVE GLUCOSE MONITOR".
FIELD OF THE INVENTION

10

The invention is related to glucose monitors.
BACKGROUND OF THE INVENTION
15

Diabetes mellitus is a medical disorder characterized by
persistent variable hyperglycemia (high blood sugar levels),
resulting either from inadequate secretion of the hormone
insulin, an inadequate response by the body's cells to insulin,
or a combination of both of these factors. The most common
forms of diabetes are type 1, type 2 and gestational diabetes.
Diabetes is a disease that causes many complications in
human normal function. As a result, the amount of glucose in
the blood increases while the cells are starved of energy. Over
the years, high blood glucose damages nerves and blood
vessels, leading to complications such as blindness, heart and
kidney disease, nerve problems, gum infections, and amputation.
People with diabetes experiences symptoms such as feeling tired, losing weight, feeling hungry or thirsty, urinating
frequently or having vision problems. Symptoms can appear
after 10 years or more living with the disease.
This disease also represents the sixth-leading cause of
death in USA. Prevention of diabetes-related complications
can be accomplished through tight control of glucose levels in
the blood. In the last decades many different glucose sensors
have been developed. For example, existing glucose sensors
and methods include near infrared spectroscopy, optical rotation, enzymatic assays, fluorescence detection, a glucose
sensing contact lenses, a biochemical catalyzed reaction
embodied as a Continuous Glucose Monitor System
(CGMS), and a product called GLUCOWATCH®. However,
none of these sensors is fully non-invasive.
The Continuous Glucose Monitoring System (Medtronic
MiniMed, Northridge, Calif.) and the GLUCOWATCH® G2
Biographer (Cygnus, Inc., Redwood City, Calif.) are
reviewed below. These two devices, each approved by the
FDA, measure a signal that is reportedly proportional to blood
glucose.
The first device for reading blood glucose levels continuously was approved by the U.S. Food and Drug Administration in June 1999. This device was the Continuous Glucose
Monitor System (CGMS) manufactured by Medtronic MiniMed. The CGMS measures interstitial fluid glucose continuously. It calculates and stores a reading every five minutes
over a 72-hour period. The CGMS does not provide the glucose results in real time, but rather downloads the readings
after they have been collected, the way a 24-hour cardiac
halter monitor provides information about cardiac rhythms
after they have occurred.
The CGMS contains a wire with a supply of glucose oxidase at the tip, which is inserted subcutaneously into the
anterior abdominal wall. This same enzyme is used in many
portable blood glucose monitors. Glucose oxidase catalyses a
biochemical reaction in the presence of glucose and Oxygen
that transfers electrons to a receiving molecule and creates an
electronic current, whose magnitude can be measured and
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A non-invasive method of sensing glucose in subjects
includes the steps of providing a sensing solution including a
metal ion from a metal salt, introducing a controlled amount
of a bodily fluid sample from a subject into the sensing solution generating an optically-based parameter derived from
directing incident light on the solution, and determining the
presence of and/or the concentration of glucose in the bodily
fluid using the parameter. The optical parameter can be
observed by absorbance, reflection, scattering or transmission of light, which can be generated in the form of spectra.
The light can be in the visible range or outside of the visible
range of the electromagnetic spectrum. Tears can be used as
the bodily fluid. The method can include a step of converting
the concentration of glucose in the bodily fluid into a concentration of glucose in the blood of the subject by the known
relationship between the concentration of glucose in the fluid
relative to the concentration of glucose in the blood. The
metal salt can be a gold salt. The sensing solution can contain
a promoter such as ammonium hydroxide. When the sensing
solution includes metal nanoparticles, preferably the nanoparticles have an aspect ratio of 1.1to2.0 and more preferably
have an aspect ratio of 1.2 to 1.8. These anisotropic metal
nanoparticles can be gold nanorods or nanoplates. The sensing solution can be heated to a temperature of 50° C. to 100°
C.
A non-invasive glucose monitoring system includes a
means of drawing a sample of a body fluid without invasion of
body tissue, a sample cell, a sensing solution of a metal salt
for placing in the sample cell with the aliquot of the body
fluid, a spectrophotometer including: a housing, a sample cell
holder for receiving the sample cell, a light source, the light
source providing light which irradiates a solution contained
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in the sample cell, a photodetector for receiving light from the
sample cell, and a microprocessor having stored software for
determining glucose concentration in blood from spectroscopic data communicably connected to the detector, such
that the microprocessor determines the glucose concentration
from spectroscopic data provided by the detector, and a power
supply, and instructions for use of the system. The power
supply can be a battery. A preferred metal salt is a gold salt.
The sensing solution can also include a promoter such as
ammonium hydroxide. The sensing solution an also include
metal nanoparticles that preferably have an aspect ratio of 1.1
to 2.0 and more preferably have an aspect ratio of 1.2 to 1.8.
The metal nanoparticles can be nanospheres, nanorods or
nanoplates. The spectrophotometer can include a heater and
can include a visual or audible alarm if the measured level of
glucose is a level that would be a danger for the subject
providing the sample. The sensing solution can be provided in
a sealed sample cell which can be plastic. The system can also
include a lachrymator so that the subject can produce tears on
demand.

measurements in a wavelength range of 10 nm, or less, such
as centered at around 560 nm for gold.
In one embodiment of the invention ("nucleation
method"), metal nanoparticles are nucleated in the solution
upon reduction of metal ions when glucose is present in the
sample. As the glucose concentration increases, it has been
found that the number of nanoparticles increases, while the
average size of the nanoparticles remains essentially the
same. This allows the concentration of glucose in the body
fluid to be determined using a spectroscopic method using the
relationship given by the Beer-Lambert law. The concentration of nanoparticles is related to the measured absorbance
via a single extinction coefficient for the uniform sized metal
nanoparticles formed by the reduction of a dissolved metal
salt to the metal particles. The relationship between the concentration of the nanoparticles and the glucose is inherent in
the reaction stoichiometry when the average size of the particles is constant as in this nucleation method.
The extinction coefficient of the nanoparticle is (E) related
to the absorbance (A) as follows:
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BRIEF DESCRIPTION OF THE DRAWINGS
A fuller understanding of the present invention and the
features and benefits thereof will be obtained upon review of
the following detailed description together with the accompanying drawings, in which:
FIG. 1 shows an exemplary noninvasive glucose detector
system according to an embodiment of the invention.
FIG. 2 is a plot showing the absorbance of a sensing solution as a function of wavelength according to an embodiment
of the invention in the wavelength range from 400 to 880 nm
for a range of glucose concentrations from 0 to 20 mM.
FIG. 3 is a plot showing the absorbance as a function of
glucose concentration according to an embodiment of the
invention at a wavelength near the gold nanoparticle absorption peak of about 560 nm.
DETAILED DESCRIPTION
A truly non-invasive method of sensing glucose comprises
the steps of providing a sensing solution including a plurality
of metal ions, and contacting a bodily fluid sample with the
sensing solution. The bodily fluid sample is preferably tears.
Metal nanoparticles are either formed (hereafter the "nucleation method") or grown on metal seeds from metal ions in
the sensing solution (hereafter the "seeding method") in the
presence of glucose. A variety of metal ions can be used with
the invention, including, but not limited to Au, Ag, Cu, Pd and
Pt ions, where these metal ions can be readily reduced to the
metallic state. Au has been found to undergo the desired
reduction. The concentration of glucose in the body fluid is
then determined which allows determination of the blood
glucose concentration, if desired.
First, an optical method generates a parameter based on a
change in at least one of absorption, reflectance and scattering
of the metal nanoparticles resulting from the contacting step.
In one embodiment of the reaction, absorption measurements
are used. In the nucleation method, higher absorbance corresponds to higher glucose levels. In the seeding method, the
magnitude of the red shift in the peak of the longitudinal
absorption band is related to the glucose concentration. In the
second step the optical parameter is correlated with glucose
concentration in the fluid. The glucose concentration in the
fluid can then be converted into a glucose level in the blood of
the subject.
A full visible light spectrum can be used for analysis.
However, useful information can be obtained by performing
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where c is the concentration of nanoparticles and 1 is the path
length of the sample. A linear relation has been found by the
present Inventor between the absorbance and the glucose
concentration for glucose concentrations as low as about 5
mM using a gold salt at a wavelength of around 560 nm to give
a constant average size gold nanoparticle as in the nucleation
method (see Example 3 below). The concentration of the
glucose in the spectrophotometry sample can be related to the
body fluid sample by the volume of body fluid introduced to
the sample. The relationship of glucose in the body fluid used
can be converted to the concentration of glucose in the blood
where the concentration profile for glucose in the body
sample has been correlated to the profile of blood glucose
levels.
In another embodiment of the invention ("seeding
method"), a plurality of anisotropic metal (e.g. gold) nanoparticles is provided in the sensing solution along with the
plurality of metal ions. The sensing solution is then contacted
with a bodily fluid sample. In the presence of glucose, the
seeded particles grow in size with a change in the aspect ratio
(AR) of the seed particles which results in a red shift in the
peak of the longitudinal absorption band. Higher glucose
concentrations have been found to result in larger red shifts.
The shift can then be correlated with the glucose concentrati on as in this case the change in the size of the metal nanoparticles is related through the glucose concentration by the
reaction stoichiometry. Again the concentration in the body
fluid can be calculated for a given volume of the body fluid
added to the sample.
Nanoparticle seeds can be obtained from a variety of
sources, including commercial sources. As used herein,
anisotropic seeds have particle shapes other than spherical
displaying an aspect ratio (AR) of at least 1.1. It has been
found that the higher the AR (e.g. length/diameter for a nanorod, or the area to thickness ratio for a nanoplate) of the
nanoparticles, the better the dynamic range. However, for AR
generally greater than about 2, sensitivity is reduced. Accordingly, ARs are preferably in the range from 1.2 to 2.0, more
preferably between 1.4and1.8 and most preferably about 1.6.
In one embodiment of the seeding method, the metal nanoparticles include surfactant along at least a portion of their
length. The surfactant present is generally associated with
certain methods that can be used to form the nanoparticles.
The metal nanoparticles formed in the presence of surfactant
are believed to display greater measurement sensitivity.
In another embodiment essentially spherical seeds, nanospheres can be used and analysis upon measuring the absorption as described above for the "nucleating method".
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Although nanospheres can be used with a diameter of 1 to 250
nm or even greater, the extinction coefficient can not generally be treated as a constant for particles in excess of about 50
nm, and corrections are generally included in the calculation
of concentration of glucose. Nanosphere seeds having diameters of 5 to 50 nm can be used, such as diameters of 5 to 10
nm or diameters of about 5 nm.
In the nucleation method a surfactant may also be added to
the sensing solution. Certain surfactants referred to as coordinating surfactants can be used to control the shape of the
nanoparticles formed, such as to form shapes other than generally spherical particles which have been found to form in
the absence of a surfactant.
Body fluids in which glucose is found is known to include
blood, saliva, urine and tears. Thus, a variety of body fluids
can be used with the invention. However, the glucose concentration in tears correlates well with the blood glucose concentration. Accordingly, in an embodiment of the invention the
body fluid is tears. Moreover, tears include a minimum of
potentially interfering materials found in other body fluids
such as saliva. It is believed that a couple of tears will be more
than enough to provide a sufficient body fluid volume to
determine the glucose concentration. The volume of tears
necessary will depend on the glucose concentration in the
tears, so diabetics potentially need smaller tear samples than
non-diabetics need. It may be necessary in some applications
to induce a subject to cry, such as by using onions or other
lachrymators to induce tearing.
Although not needed to practice the present invention and
not seeking to be bound to the theory presented, reaction
details follow that are believed to be operable. The operable
generalized reaction utilized by the invention is a redox reaction where glucose functions as the reducing agent according
to the following (only reduction product shown):
1. (nucleation method) metal salt+glucose--;.metal nanoparticles form.
2. (seeding method) metal salt+glucose+anisotropic metal
nanoparticle seeds--;.metal nanoparticles grow and theAR of
the nanoparticles change due to the growth.
The above reactions are believed to be made possible based
on the equilibrium of glucose in solution between the openchain aldehyde alcohol form and the cyclic hemiacetal form
as shown in schematic (1) below. The presence of the aldehyde can be detected through a reaction with chloroauric acid
in aqueous solution, in a manner similar to the Toll en's silver
mirror test for aldehydes shown as (2) below.

ation method or grow in the seeding method during the oxidation of glucose. Gluconic acid is the carboxylic acid forms
by the oxidation of the first carbon of glucose and has the
chemical formula C 6 H 120 7 . In the nucleation method as more
nanospheres form, absorption at the wave length of 560 nm
changes proportionally to the glucose concentration. In the
seeding method, as the AR of the nanoparticles change, a
resulting red shift of the wavelength of the peak absorption
can be directly correlated to the amount of glucose oxidized.
In either method, the absorbance spectruni (or portion
thereof) can be measured using a UV-Vis spectrometer, which
can be as small as a cigarette box, or even smaller.
Thus, as shown above, the open chain aldehyde form of
glucose acts as a reducing agent and reacts with a metal salt to
form metal nanoparticles in the nucleation method or modify
theAR in the seeding method. An above ambient temperature,
such as about 50 to about 100° C. can be used to increase the
reaction rate.
Results obtained using silver salts for the nucleation
method have provided useful results. However, gold salts
were found to provide much better results. An exemplary
reaction for an exemplary gold salt is shown below. The
reaction product is gold nanoparticles (nanospheres (NS)
absent surfactant addition) shown in reaction (3) below:
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In the presence of a gluconic acid salt, which is believed to
stabilize metal nanoparticles, nanospheres form in the nucle-

l'J.

AuNS solution

Heating above room temperature can accelerate of the nanoparticle formation and growth, as noted above, where the
solution can be heated, for example to a temperature of70 to
80° C. Ammonium hydroxide shown above has been found to
promote the reaction.
The invention has been found to provide a low limit of
detection as is described in the example below for the use of
a gold salt. The invention gives highly selective, reliable, and
reproducible results and can be embodied in a system that is
portable, simple, low cost and noninvasive (no painful testing).
A schematic of an exemplary glucose detector system 100
according to an embodiment of the invention is shown in FIG.
1. System 100 includes a housing 105 having a sample cell
holder 110 of appropriate dimensions for insertion of a
sample cell 115 such that the proper orientation for the transmission of light from a light source 120 to a photodetector
125, where a light path is shown by a dashed line in FIG. 1, is
achieved and the system can be sealed from light external to
the housing 105. The sealing of the light can be by any means
such as a door, cap, or plug associated with the housing 105,
sample cell holder 110 and/or sample cell 115. The sample
cell 115 can also be used to store a desired concentration of a
metal salt solution for mixture with the prescribed quantity of
the body fluid. Although shown as a direct light path in FIG.
1, the system can include mirrors, lenses, and diffraction
gratings (not shown) as required to deliver the light as desired
to the photodetector 125.
In general, the sample cell 115 can be made from any
material of sufficient transparency at the range of wavelengths used for the analysis of the sample. The sample cell
115 can be sufficiently small such that the volume of a single
tear can be mixed with a smaller volume of a sensing solution
containing a metal salt. The volume of the sample cell can be
about 0.1 to about 1 mL or greater. The material forthe sample
cell 115 can be quartz, glass, or a plastic. Battery 130, such as
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a lithium ion battery, provides power for the various components of system 100. Microprocessor 135 includes associated
memory which stores operating software. Microprocessor
135 is communicably connected to light source 120. Light
source 120 provides light which irradiates a solution contained in sample cell 115. Photodetector 125 receives light
transmitted through the solution in sample cell 115 and converts the light into an electrical signal. The electrical signal is
communicated to microprocessor 135. Microprocessor 135
determines the glucose concentration from data provided by
detector 125. The microprocessor 135 can instruct the collection of multiple readings of the optical signal over time such
that the complete oxidation of the glucose in the sample can
be assured by determining that a maximum signal is reached.
Additionally, a means of controlled heating (not shown) of
sample cell 115 to a predetermined temperature can be
included. In a preferred embodiment, ifthe glucose concentration is above or below a predetermined concentration,
microprocessor commands a light (e.g. blinking red light) or
audible alarm 140 to activate. The alarm can also be used to
convey other information, such as the viability of the sample
for subsequent reuse. Although not shown, system 100 can
include a transmitter and antenna to allow data to be monitored at a remote location.
In operation, a user will provide a tear sample and place a
predetermined volume of the tear sample into sample cell
115. The specific volume of a sensing solution including a
specific concentration of a metal salt can then be added and
the components mixed as needed. Alternately, the opposite
order of addition of reagents can be carried out. In one
embodiment the sample cell 115 is provided with a sealed
sensing solution of a specific concentration and volume
which has been programmed into the microprocessor such
that the sample can be formed upon introduction of a specific
volume of the body fluid either through the seal or upon
removal of the seal. In another embodiment the sample cell
can be used for the collection of a sample of the bodily fluid
and a specific portion of the sensing solution of a metal salt
can be introduced to the sample cell 115. Sample cell 115 is
then inserted into system 100 and the measurement process is
begun. The microprocessor can then determine the glucose
present in the bodily fluid by performing a differential measurement. Following use, contents of the sample cell 115 can
be disposed of, or stored and subsequently reused depending
upon the amount of metal salt remaining in the sample cell
which can be calculated from the measured optical signal. If
reused, an initial optical measurement can be made prior to
adding the bodily fluid or the stored previous measurement
can be used in the determination of the glucose level. The
magnitude of the optical measurement can be used to determine the viability of reusing the sample cell.
Using the glucose measurement, diagnosing diabetes and a
variety of other diseases which are associated with an
increase or decrease in glucose can be realized. Regarding
diabetes, the detection limit is low enough to detect levels of
glucose in healthy persons. Using the inventive method,
potential diabetic problems can be detected before diabetes
has been diagnosed.

presence of various concentrations of glucose in an ammonium hydroxide 2% solution. The concentration of glucose in
solution varied from 0 to 20 mM. The reaction was performed
at about 70° C. FIG. 2 shows the absorbance of the sensing
solution as a function of wavelength in the wavelength range
from 400 to 880 nm where glucose was added to achieve
solution concentrations from 0 to 20 mM. An absorption peak
can be seen at about 560 nm where higher glucose concentrations resulted in higher measured absorbance levels.
FIG. 3 shows the absorbance dated shown in FIG. 2 at a
wavelength near the gold nanoparticle absorption peak of
about 560 nm. As shown in FIG. 3, the higher the glucose
concentration, from about 6 mM to 20 mM, the higher the
value of the absorbance. The relationship is linear. A level of
6.1 mM glucose in the tear is known to correspond to about a
110 mg/dL glucose level in the blood, which is in the normal
blood glucose range from 70 to 110 mg/dL. Due to the relationship between the glucose level in tears and the glucose
level in blood, the relationship between measured absorbance
and blood glucose can be stored, such as in a non-volatile
memory in a microprocessor-based system including a spectrophotometer. The measured absorbance provided by a spectrophotometer allows the determination of the blood glucose
level by the relationship of the nanoparticle concentration to
the glucose concentration from the body sample aliquot and
the relationship of the glucose level of a body sample to the
blood level. The dependence of the absorbance of the gold
nanoparticles solution with glucose concentrations as low as
that in common in non-diabetic tears, several mM, makes
sensors according to the invention suitable for direct applications in biomedical sensing, including measurements by the
subjects themselves.
It is to be understood that while the invention has been
described in conjunction with the preferred specific embodiments thereof, that the foregoing description as well as the
examples which follow are intended to illustrate and not limit
the scope of the invention. Other aspects, advantages and
modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.
The Abstract of the Disclosure is provided to comply with
37 C.F.R. §1.72(b), requiring an abstract that will allow the
reader to quickly ascertain the nature of the technical disclosure. It is submitted with the understanding that it will not be
used to interpret or limit the scope or meaning of the following claims.
I claim:
1. A method of determining glucose concentrations m
bodily fluids, comprising:
providing a sensing solution comprising a plurality of
metal ions;
introducing a bodily fluid sample from a subject into said
sensing solution, wherein if glucose is present in said
bodily fluid sample said glucose reduces said plurality of
metal ions to form metal nanoparticles or increases a
size of metal nanoparticle seeds if said metal nanoparticle seeds are also provided in said sensing solution;
directing incident light at said sensing solution after said
introducing;
measuring at least one optically-based parameter responsive to said directing of said incident light, and
determining a concentration of said glucose in said bodily
fluid sample based on an amplitude of said opticallybased parameter wherein a higher absorbance corresponds to a higher glucose concentration or a magnitude
of a red wavelength shift of a peak absorption wavelength when said metal nanoparticle seeds are provided
in said sensing solution and said optically-based param-
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EXAMPLES
It should be understood that the Examples described below
are provided for illustrative purposes only and do not in any
way define the scope of the invention.
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Nucleation Embodiment
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Gold nanospheres were synthesized using a 2.4x10- 5 M
chloroauric acid tri-hydrated (HAuC1 4 .3H 2 0) solution, in the
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eter is wavelength, wherein a higher red wavelength
or increases a size of metal nanoparticle seeds if metal
nanoparticle seeds are also provided in said sensing
shift corresponds to a higher glucose concentration.
solution; and
2. The method of claim 1, wherein said optically-based
a spectrophotometer including a light source for measuring
parameter comprises absorbance, reflection, scattering or
at least one optically-based parameter responsive to light
transmission of said incident light.
from said light source directed at said sample cell, and a
3. The method of claim 1, wherein said measuring commicroprocessor that includes associated memory for
prises generating a spectrum.
determining a concentration of said glucose in said
4. The method of claim 1, wherein said bodily fluid sample
bodily fluid sample based on an amplitude of said opticomprises tear fluid.
cally-based parameter or a wavelength shift of a peak
10
5. The method of claim 1, further optionally comprising
absorption wavelength when said nanoparticle seeds are
provided in said sensing solution and said opticallyconverting said concentration of glucose into a concentration
based parameter is wavelength.
of glucose in blood of said subject using a correlation relation
14. The system of claim 13, wherein said plurality of metal
between a glucose concentration in said bodily fluid sample
ions comprises gold ions.
and glucose concentration in said blood.
15
15. The system of claim 13, wherein said sensing solution
6. The method of claim 1, wherein said plurality of metal
further comprising a promoter that promotes said glucose
ions comprise gold ions.
reducing said plurality of metal ions.
7. The method of claim 1, wherein said sensing solution
16. The system of claim 15, wherein said promoter comfurther comprises a promoter that promotes said glucose
prises animonia hydroxide.
reducing said plurality of metal ions.
20
17. The system of claim 13, wherein said sensing solution
8. The method of claim 7, wherein said promoter comprises
further comprises said metal nanoparticle seeds, said metal
nanoparticle seeds comprising a plurality of anisotropic metal
ammonium hydroxide.
nanoparticles.
9. The method of claim 1, wherein said sensing solution
18. The system of claim 17, wherein said plurality of anisofurther comprises said metal nanoparticle seeds, said metal
nanoparticle seeds comprising a plurality of anisotropic metal 25 tropic metal nanoparticles have an aspect ratio of 1.1 to 2.0.
19. The system of claim 17, wherein said plurality of anisonanoparticles, and said optically-based parameter comprises
tropic metal nanoparticles have an aspect ratio of 1.2 to 1.8.
said wavelength shift.
20. The system method of claim 18, wherein said plurality
10. The method of claim 9, wherein said plurality of anisoof anisotropic metal nanoparticles comprise nanospheres,
tropic metal nanoparticles have an aspect ratio of 1.2 to 1.8.
30 nanorods or nanoplates.
11. The method of claim 9, wherein said plurality of aniso21. The system of claim 13, wherein said spectrophotomtropic metal nanoparticles comprise gold nanorods or nanoeter further comprising a visual or audible alarm.
plates.
22. The system of claim 13, wherein said sensing solution
12. The method of claim 1, further comprising heating said
is provided in a sealed sample cell.
sensing solution to a temperature of 50° C. to 100° C.
35
23. The system of claim 13, wherein a correlation relation
13. A glucose monitoring system, comprising:
between glucose concentration in said bodily fluid sample
a sample cell;
and a glucose concentration in blood is stored in said memory,
a sensing solution comprising a solution comprising a pluand wherein said microprocessor converts said concentration
rality of metal ions in said sample cell together with a
of glucose in said bodily fluid sample into a concentration of
bodily fluid sample from a subject, wherein if glucose is
40 glucose in blood of said subject.
present in said bodily fluid sample said glucose reduces
said plurality of metal ions to form metal nanoparticles
* * * * *

